The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SANA | +41.53% | N/A | N/A | -90% |
| S&P | +13% | +86.41% | +13.26% | +75% |
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
Good news drove shares of these stocks through the roof last week, but investors should be more concerned about their paths forward.
The company announced details of research on two of its pre-clinical therapies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$3.20M | 21.1% |
| Market Cap | $918.39M | -0.8% |
| Market Cap / Employee | $4.73M | 0.0% |
| Employees | 194 | -40.9% |
| Net Income | -$42.15M | 29.7% |
| EBITDA | -$42.31M | 26.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $107.55M | -17.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $67.87M | -20.6% |
| Short Term Debt | $14.37M | 35.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.13% | 4.2% |
| Return On Invested Capital | -60.08% | -7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.47M | 47.3% |
| Operating Free Cash Flow | -$29.43M | 43.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.24 | 1.50 | 2.94 | 6.68 | 145.34% |
| Price to Tangible Book Value | 3.92 | 7.42 | 66.49 | -10.59 | -260.20% |
| Enterprise Value to EBITDA | -6.72 | -8.46 | -16.00 | -20.09 | 32.29% |
| Return on Equity | -99.2% | -71.4% | -109.1% | -96.1% | 3.45% |
| Total Debt | $94.20M | $91.31M | $85.49M | $82.24M | -14.41% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
